title: Lipidfiltration--safe and effective methodology to perform lipid-apheresis.
abstract: Familial hypercholesterolemia (FH) not adequately responding to diet and drug therapy represents an indication for extracorporeal lipid-apheresis, which has become an highly effective and approved therapy for those patients in several countries. Based on different methodology, five treatment options of lipid-apheresis exist and are in widespread practical use covered by regular reimbursement in Germany. All methods are safe and demonstrate equivalent efficacy of reducing LDL cholesterol with respect to the single apheresis session as well as during long-term treatment. Therefore German reimbursement guidelines leave the choice of the method to the discretion of the apheresis center. Related to properties of the used technology all methods exhibit characteristic patterns of additional plasma protein elimination, which do not impair, but in part may increase the therapeutic benefit of lipid-apheresis. Fibrinogen reduction has to be mentioned as an example. The Lipidfiltration system is based on plasmafiltration previously referred to as membrane differential filtration (MDF), synonymous with double filtration plasmapheresis (DFPP). The new term Lipidfiltration was the result of technological progress in the manufacturing process of the plasmafilter resulting in enhanced sieving characteristics and capacity. The Lipidfiltration system is completed by a specifically designed therapy machine with optimised performance characteristics.
authors.affiliation: Apheresis Research Institute, Stadtwaldguertel 77, 50935 Cologne, Germany. afi@apheresis-research.de
authors.forename: Reinhard
authors.initials: R
authors.lastname: Klingel
authors.forename: Patrick
authors.initials: P
authors.lastname: Mausfeld
authors.forename: Cordula
authors.initials: C
authors.lastname: Fassbender
authors.forename: Britta
authors.initials: B
authors.lastname: Goehlen
mesh_terms: D001781:Blood Component Removal / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood*; D010956:Plasmapheresis / Q000379:methods; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL